The beneficial effect on NASH is likely mediated by the FGFR1c/KLB complex, while the contribution of the FGFR4/KLB complex and lowering of bile acids preventing hepatocyte damage and subsequent fibrosis is not fully established in NASH. This evidence concerns the gene FGFR4 and metabolic dysfunction-associated steatohepatitis.